Why are they combined rather than used separately?

The GHRH pathway (CJC-1295) and the ghrelin pathway (Ipamorelin) are independent. Activating both simultaneously produces a GH response substantially larger than stimulating one pathway alone. The combination allows less frequent dosing than sermorelin while producing a potent GH pulse.

How often is it administered?

Typically 2-3 times per week — less frequently than sermorelin which is usually daily. Your physician will determine the specific protocol.

How does it compare to sermorelin?

Sermorelin acts on the GHRH pathway only and has a short half-life requiring daily administration. CJC-1295 with DAC has an extended half-life and when combined with Ipamorelin targets two pathways simultaneously. Many physicians consider CJC-1295 + Ipamorelin more potent — but it is also less established clinically. Your physician will determine which is appropriate.

Is CJC-1295 + Ipamorelin FDA-approved?

No. Neither CJC-1295 nor Ipamorelin is FDA-approved. Both are compounded as investigational peptides by licensed 503A pharmacies under physician supervision. They have not been evaluated by the FDA for safety, efficacy, or quality.

What labs are monitored?

IGF-1 (a downstream marker of GH activity) and fasting glucose are typically monitored during therapy. Your physician will determine appropriate monitoring intervals.

Who prescribes and compounds this?

Prescribing by licensed physicians at Arora Health & Aesthetics LLC. Compounded by VialsRX, Houston TX — USP-compliant 503A laboratory.

Can women use CJC-1295 + Ipamorelin?

Yes. The combination is prescribed for both men and women. Women in perimenopause and menopause often find benefit as GH optimization complements HRT by addressing the additional dimension of GH decline.

Part of the pillar guide: Peptide Therapy — Complete Guide

kindr

GHRH Analogue + GHRP · Synergistic Combo

Two peptides. Two pathways. One optimized GH pulse.

CJC-1295 and Ipamorelin are prescribed together because they work through different but complementary mechanisms — producing a growth hormone pulse significantly greater than either peptide achieves alone. The most popular GH secretagogue combination in physician-supervised peptide therapy.

Neither CJC-1295 nor Ipamorelin is FDA-approved. Both are investigational peptides compounded under physician supervision. Evidence is primarily preclinical and from small observational studies. Physician evaluation required and a prescription is not guaranteed.

Request Physician Evaluation →

· Physician evaluation required· Licensed 503A pharmacy· All 50 US states

CJC-1295

GHRH pathway

Stimulates pituitary GH release

Ipamorelin

Ghrelin pathway

Independent GH pulse signal

Amplified

GH Pulse

2x-10x

greater GH release with combination vs single peptide in research models

Neither CJC-1295 nor Ipamorelin is FDA-approved. Both are investigational peptides. Compounded by VialsRX under 503A. Physician evaluation required.

Understanding the combination.

GHRH Analogue

CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the same pathway sermorelin targets. The key difference is the Drug Affinity Complex (DAC) modification in CJC-1295 with DAC, which dramatically extends its half-life by binding to albumin in the bloodstream. This produces sustained GHRH activity over days rather than hours, leading to a larger and more prolonged GH release pattern.

Half-life: 6-8 days (CJC-1295 with DAC) vs 30 minutes (sermorelin)

GHRP / Ghrelin Mimetic

Ipamorelin

Ipamorelin is a growth hormone releasing peptide (GHRP) — it works through the ghrelin receptor, a completely different pathway than GHRH. This is why combining it with CJC-1295 produces synergistic effects: two independent signals reaching the pituitary simultaneously. Ipamorelin is considered highly selective — producing GH release with minimal effect on cortisol or prolactin, which distinguishes it from older GHRPs like GHRP-2 or GHRP-6.

Half-life: 2 hours · Highly selective

Why they are prescribed together

The GHRH pathway (CJC-1295) and the ghrelin pathway (Ipamorelin) are independent GH release mechanisms. Stimulating both simultaneously produces a GH pulse substantially larger than either produces alone. Research in animal models and early human studies suggests the combination effect is synergistic rather than simply additive. This is why CJC-1295 + Ipamorelin has become the most commonly prescribed peptide combination in growth hormone optimization protocols.

What physicians prescribe this combination for.

Evidence for CJC-1295 + Ipamorelin combination is primarily preclinical and from small observational studies. No large-scale randomized controlled trials have been completed. Your physician will review available evidence with you.

Body Composition

GH promotes lipolysis and lean muscle preservation. The combination is widely used for improving muscle-to-fat ratio in adults experiencing age-related changes.

Sleep Quality

GH release is highest during slow-wave sleep. Many patients report improved sleep depth within the first weeks of therapy — which itself enhances the natural GH cycle.

Recovery

Enhanced GH signaling supports cellular repair and protein synthesis. Athletes and active adults report faster recovery from exercise and injury.

Energy and Cognitive Clarity

Optimized GH levels are associated with improved daytime energy and cognitive function in adults with GH decline.

Skin and Collagen

GH stimulates IGF-1 which supports collagen production. Skin quality improvements are reported by many patients — particularly relevant for women in menopause experiencing simultaneous collagen decline.

Metabolic Rate

Growth hormone has direct metabolic effects — influencing glucose metabolism and fat oxidation. Optimized GH may support metabolic rate maintenance in aging adults.

CJC-1295 + Ipamorelin vs Sermorelin.

Feature	Sermorelin	CJC-1295 + Ipamorelin
Pathways	GHRH only	GHRH + Ghrelin
Half-life	30 min	Days (CJC) / Hours (Ipa)
GH pulse size	Moderate	Larger (synergistic)
Dosing frequency	Daily	2-3x per week
Selectivity	Moderate	High (Ipamorelin)
Clinical data	More established	Less established
Cost	Lower	Higher

Neither is universally superior. Physician determines the appropriate protocol based on your goals, health history, and response.

Learn more about sermorelin →

Who benefits

Adults over 30 with GH decline symptoms
Men on TRT seeking GH optimization
Women in menopause with body composition changes
Active adults with slow recovery
Those who prefer less frequent dosing than sermorelin

Contraindications

Active malignancy or cancer history
Diabetic retinopathy
Pregnancy or breastfeeding
Known hypersensitivity to GHRH or ghrelin
Active acromegaly

Side effects

Injection site reactions
Water retention (transient)
Headache
Tingling or numbness (dose-dependent)
Increased hunger (Ipamorelin — mild)
IGF-1 elevation (monitored by physician)

Request your CJC-1295 + Ipamorelin evaluation.

Complete this form to be evaluated for compounded CJC-1295 + Ipamorelin. A licensed physician will review your submission within 24 hours.

Full name

Email address

Phone number

Date of birth

State of residence

Current weight

Height

Primary concern

Current medical conditions

HypertensionHigh cholesterolType 2 diabetesSleep apneaThyroid conditionHistory of cancerNone of the above

Current medications

Additional information

I understand that neither CJC-1295 nor Ipamorelin is FDA-approved. Both are investigational peptides. I consent to physician evaluation and understand that a prescription is not guaranteed.I consent to the collection and processing of my health information in accordance with kindr Health's HIPAA Privacy Notice.

Neither CJC-1295 nor Ipamorelin is FDA-approved. Both are investigational peptides. Compounded by VialsRX under 503A. Clinical services by Arora Health & Aesthetics LLC. Prescription not guaranteed.

Frequently asked questions.

CJC-1295 is a long-acting synthetic analogue of GHRH (growth hormone-releasing hormone). Ipamorelin is a selective growth hormone releasing peptide (GHRP) that works through the ghrelin receptor. Together they stimulate growth hormone release through two independent pathways simultaneously — producing a synergistic GH pulse larger than either achieves alone.

Two pathways. One evaluation. Start today.

Request Evaluation →

Neither CJC-1295 nor Ipamorelin is FDA-approved. Both are investigational peptides. Compounded by VialsRX under 503A. Clinical services by Arora Health & Aesthetics LLC. Prescription required. Not guaranteed.

Related kindr resources

Sermorelin →BPC-157 →Retatrutide →

Keep reading

Sermorelin

Single-molecule GHRH analog — compare frequency and effects.

Read Sermorelin →

BPC-157

Body-protection compound studied for repair and gut health.

Read BPC-157 →

PT-141

Melanocortin agonist studied for sexual desire and arousal.

Read PT-141 →

Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026

Latest from the Journal

Weight & metabolism
HRT vs GLP-1 for menopause weight loss: which is right for you?
Hormone therapy addresses the hormonal causes of midlife weight gain. GLP-1s like semaglutide target appetite and metabolism. Here is how they differ — and when to use one, the other, or both.
Read HRT vs GLP-1 for menopause weight loss: which is right for you? →
Lifestyle
Strength training in menopause: the single most important habit after 40
Estrogen loss accelerates muscle and bone decline. Resistance training — done correctly — is the closest thing we have to a medication for it.
Read Strength training in menopause: the single most important habit after 40 →
Perimenopause
Understanding perimenopause: the years before menopause
Perimenopause can begin in your late 30s or 40s and last up to a decade. Here is what is happening hormonally and what actually helps.
Read Understanding perimenopause: the years before menopause →